Nutex Health

NUTX

Market cap $736M

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health, Inc. ("Nutex" or the "Company") (NASDAQ: NUTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health, Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders.

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Nutex Health, Inc. (“Nutex” or the “Company”) (Nasdaq: NUTX) for potential violations of the federal securities laws.

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health, Inc. ("Nutex" or the "Company") (NASDAQ: NUTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Nutex Health, Inc. (“Nutex” or the “Company”) (Nasdaq: NUTX) for potential violations of the federal securities laws.

Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript

ATLANTA, March 06, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Nutex Health, Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX) complied with federal securities laws. On March 5, 2026, Nutex Health announced its financial and operating results for the fourth quarter and fiscal year 2025, revealing a revenue decrease of $105.9 to $151.7 million for the three months ended December 31, 2025 due in part to a “one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process. ” The price of the Company's stock dropped following this news.

Block & Leviton is investigating Nutex Health, Inc. (Nasdaq: NUTX) for potential securities fraud. Investors should contact the firm to recover losses.

FULL YEAR 2025 HIGHLIGHTS: Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4% Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 million Diluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024 EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6% Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6% Net cash from operating activities of $248.1 million for 2025 HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced fourth quarter and fiscal year 2025 financial results for the twelve months ended December 31, 2025. Nutex Health is a physician-led, healthcare services and operations company with 27 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing physician network.